EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2

Hui Yu, Xianrong Xu, Lirong Zhu, Shengjie Chen, Jincheng He iD

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Hui Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Ubiquitination, Tumor Suppressor Proteins, Adenocarcinoma of Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We tried to elucidate the possible roles of maternal embryonic leucine pull chain kinase (MELK) in lung adenocarcinoma (LUAD) growth and metastasis. Differentially expressed genes in LUAD samples were analysed by the GEPIA database. Clinical tissue samples and cells were collected for MELK, EZH2 and LATS2 expression determination. Co‐IP assay was used to verify the interaction between EZH2 and MELK; CHX tracking assay and ubiquitination assay detected the degradation of MELK on EZH2 ubiquitination. ChIP assay detected the enrichment of EZH2 and H3K27me3 on the LATS2 promoter region. LUAD cells were selected for in vitro validation, and the tumorigenic ability of LUAD cells was also observed in a transplantation tumour model of LUAD nude mice. MELK and EZH2 were highly expressed in LUAD samples, while LATS2 was lowly expressed. MELK interacted with EZH2 to inhibit its ubiquitination degradation; EZH2 elevated H3K27me3 modification in the LATS2 promoter to lower LATS2 expression. Silencing MELK or EZH2 or overexpressing LATS2 restrained LUAD cell proliferation and invasion, and facilitated their apoptosis. Silencing MELK or EZH2 or overexpressing LATS2 suppressed tumour formation in nude mice. This study demonstrated that MELK aggravated LUAD by upregulating EZH2 and downregulating LATS2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesUbiquitinationTumor Suppressor ProteinsAdenocarcinoma of LungEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticLung NeoplasmsHistonesCell ProliferationMice, NudeHumansAnimalsMiceMethylationCell Line, TumorPromoter Regions, GeneticApoptosisFemaleMale

Stichwörter der Autor:innen

EZH2H3K27me3LATS2MELKdegradationlung adenocarcinomamethylation modificationproliferation invasionubiquitination

Substanzen

Protein Serine-Threonine KinasesLATS2 protein, humanTumor Suppressor ProteinsEnhancer of Zeste Homolog 2 ProteinHistonesEZH2 protein, humanMELK protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Surgical Department, Danyang Maternal and Child Health Hospital, Danyang, China.

ORCID-Profile: Jincheng He

Zitieren

APA

Yu, H., Xu, X., Zhu, L., Chen, S., & He, J. (2024). MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18216

Vancouver

Yu H, Xu X, Zhu L, Chen S, He J. MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18216

BibTeX
@article{Yu2024,
  author = {Yu, Hui and Xu, Xianrong and Zhu, Lirong and Chen, Shengjie and He, Jincheng},
  title = {MELK aggravates lung adenocarcinoma by regulating EZH2 ubiquitination and H3K27me3 histone methylation of LATS2},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18216}
}
Kostenlos starten →